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Individuals suffering from psoriasis are treated with a 
combination of psoralen and UV A radiation, com-
monly referred to as "PUVA" therapy. Epidemio-
logic studies have shown that PUV A therapy is a risk 
factor for skin cancer in psoriasis patients. Although 
PUV A treatment induces skin cancer in laboratory 
animals, it is unknown whether the increased inci-
dence of skin cancer reported in PUV A-treated pso-
riasis patients is due to the carcinogenic effects of 
PUV A or due to other factors such as UVB. Because 
UV and PUV A induce different types of DNA damage 
resulting in unique types of p53 mutation, we inves-
tigated whether skin cancers from PUV A-treated 
psoriasis patients have PUV A-type or UV -type p53 
mutations. Analysis of 17 squamous cell carcinomas 
(sees) from Austrian PUV A-treated patients re-
vealed a total of 25 p53 mutations in 11 sees. A 
majority of p53 mutations occurred at 5'TpG sites. 
P soriasis is a hyper-proliferative chronic skin disorder affecti11g more .than four million people in the United States and an estimated 2% of the worldwide population (Krueger et al, 1984). Modern photochemotherapy for psoriasis, known as psoralen plus ultraviolet A (PUVA), 
was introduced in 197 4 and consists of oral or topical administration 
of psoralen, followed by UV A (320-400 mn) radiation (Haber, 
1974; Parrish eta/, 1974; Honigsmann et al, 1987). Although PUV A 
therapy is highly effective for psoriasis, achieving 80-90% clearance 
in 8-12 wk (Weinstein and White, 1993), this treatment is usually 
administered on a long- terrn basis to prevent recurrence of the 
disease or to treat new lesions. Several studies have shown, 
however, that PUV A is a potent mutagen and a carcinogen (Griffin, 
1959; Pathak et al, 1959; Kripke et a/, 1982; Ananthaswamy, 1985; 
Sage et al, 1993; Yang el a/, 1994; Gunther et al, 1995; Nataraj et al, 
1996). In addition, clinical follow-up studies have indicated that 
PUVA therapy is a risk factor for the development of squamous cell 
carcinoma (SCC) i11 humans. Several studies have shown that 
psoriasis patients who had received extensive PUV A therapy had a 
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Although previous studies have shown that 5 'TpA 
sites are the primary targets for PUV A mutagenesis, 
substitutions at 5'TpG sites are also quite common. 
Interestingly, a sizable portion of p53 mutations de-
tected were e~T or ee~TT transitions, character-
istic of UV -induced mutations. Because some psori-
asis patients had substantial exposure to UVB before 
PUV A therapy and because the light sources used in 
PUV A therapy contained small but significant wave-
lengths in the UVB region, it is possible that the e~T 
and ee~TT transitions detected in sees from 
PUVA-treated patients were induced by UVB. None-
theless, our results indicate that both PUV A and UVB 
may play a role in the development of skin cancer in 
Austrian psoriasis patients who undergo PUV A ther-
apy. Key words: carcittogettesis!m~ttagettesislskitt cancer. 
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10-fold increase in the incidence of sec over that ll1 the general 
population (Stem ct al, 1979, 1984, 1988; Bruynzeel, 1987; Lin-
delof et a/, 1991; Stern, 1991; Lever and Farr, 1994). Conversely, 
some European and Japanese PUVA cohort studies did not find any 
association between PUV A therapy and an il1creased incidence of 
SCC (Lindskov, 1983; Tanew et a/ , 1986; Henseler et al, 1987; 
Torinuki and Tagami, 1988) . A more in-depth examination of the 
data in these studies revealed some differences, however. For 
example, in the United States studies, in which a strong association 
between PUV A and SCC incidence was noted, doses above 1500 
J/cm2 were administered to a greater percentage of the patients; i11 
contrast, the European studies reported lower UV A exposure 
levels . There were also major differences between the studies in 
follow-up time, treatment regimen, cohort size, and skin type 
analyzed. When all these factors were weighed iJ1to the results of 
the European studies, the results seemed to agree with the original 
findings of Stern et al (reviewed in Studniberg and Weller, 1993). 
Although PUV A-treated patients are at an i11ereased risk for 
developing skin cancer, the etiology of and molecular basis for the 
increased i11cidence of SCC ill PUV A-treated psoriasis patients are 
unknown. There could be several e;x:planations for the increased 
i11cideuce of skin cancer in PUV A-treated patients. First, because 
PUV A is mutagenic and carcinogenic, skin cancers arising in 
PUV A-treated patients may be initiated or induced by PUV A. 
Second, because PUV A treatment is immunosuppressive (Kripke et 
a/, 1983; Morison and Kripke, 1984), it may permit the growth of 
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skin cancers induced by other carcinogenic agents. Third, because 
many psoriasis patients undergo treatment with UVB (290-320 
nm) in addition to PUVA (LindelOf and Sigurgeirsson, 1993), it is 
possible that UVB is the inducing carcinogen. There is very little 
evidence, however, to support any of these hypotheses. 
The p53 tumor suppressor gene is a major target for carcinogen-
specific mutations, and as such, it may be possible to use tllis gene 
as a molecular marker to identify the etiology of skin cancers 
induced in PUV A-treated patients. Because UV and PUV A induce 
different types of lesions in DNA, we hypothesized that mutations 
induced by these agents may also be dilferent. Whereas UV induces 
primarily cyclobutane-type pyrinlidine dimers and pyrinlidine (6-
4)-pyrimidone photoproducts (Rosenstein and Mitchell, 1987), 
PUV A induces monofunctional adducts and DNA cross-links 
(Musajo et al, 1967a, 1967b; Cole, 1971; Ben-Hur and Elkind, 
1973; Dall'Acqua, 1977; Song and Tapley, 1979; Gasparro et a/, 
1985). Both human skin cancers and UV-induced mouse skin 
cancers exhibit a lligh frequency of UV-signature (C~T and 
cc~ TT) mutations (Brash et al, 1991; Kress eta!, 1992; Rady eta/, 
1992; Campbell et al, 1993; Dumaz et al, 1993; Kanjilal et al, 1993; 
Moles et al, 1993a; Sato et al, 1993; Ziegler eta/, 1993, 1994; Kubo 
et al, 1994; Nakazawa et al, 1994; Nelson eta/, 1994; Van der Riet 
eta/, 1994; Ren eta/, 1996). In contrast, PUV A-induced mouse skin 
cancers contain p53 mutations at 5'-TA or 5'-TAT sequences that 
are quite distinct from those found in UV-induced skin cancers 
(Nataraj et al, 1996). 
In this study, we analyzed SCCs from PUV A-treated psoriasis 
patients from Graz, Austria for p53 mutation to determine whether 
they harbored PUV A-type or UV - type mutations. The results 
indicated thatp53 mutations were present in 65% ofSCCs analyzed 
and that the mutational pattern was dilferent from those found in 
SCCs arising in the general population. Approximately half of the 
p53 mutations were located at S'TpG sites and about one tllird were 
UV -signature type, suggesting that both PUV A and UV contt;b-
uted to the development of skin tumors. 
MATElUALS AND METHODS 
Patient Characteristics and History of PUV A Treatment The 
patients were all Caucasians from Graz, Austria and ranged in age from 34 
to 58 y at the commencement of PUV A therapy. Seven were male and four 
Were female. Most SCCs examined in tlus study arose in patients approxi-
mately 11- 17 y after the first PUV A treatment and 3 mo to 11 y after the last 
treatment (data not shown). Most patients included in the study had 
multiple SCCs after PUVA treatment. h1 addition to 8-methoxy psoralen 
(8-MOP) and UVA treatment, three patients also received 5-MOP and 
UV A treatment. Although 5-MOP and 8-MOP have similar photobinding 
properties, 5-MOP appears to be more cytotoxic in ''itro (Ashwood-Snlith et 
al, 1980). T he cumulative 5-MOP/UVA doses used in therapy were not 
very high, but the total UV A dose for 8-MOP /UV A treatment in some 
patients was as bigh as approximately 7000 J I em 2 . The UV A lamps used in 
PUV A therapy in Europe emit approximately 99.5% of their energy in the 
UV A region and about 0.5% in the UVB region (Diffey, 1986). Moreover, 
9 of 11 patients also had received extensive prior treatment wiili UVB 
radiation. It was difficult, however, to determine the total amount of UVB 
received by these patients because UVB therapy was admizustered at 
dilferent dermatology clinics or institutions over a period of 10 - 15 y before 
the commencement of PUV A therapy. Therefore, access to such treatment 
records was difficult. 
DNA Extraction DNA was extracted from paraffin-embedded sections 
using the method of Heller et al (1991), with minor modifications. Five- to 
1 0-ILm sections were deparaffitlized by "'ylene, suspended in 100-200 ILl of 
lysis buffer (SO nM KCl, 10 mM Tris, pH 8.3, 1.5 mM MgC12 , 0 .01% 
gelatin, 0.5°/.1 Tween 20, and 0.5 mg proteinase K per ml), and sonicated 
with sterile glass beads (Sigma Chenucal Co., St . Louis , MO) at 45 °C for 
5-10 min using a Branson Model 2200 sonicating water bath (Branson 
Ultrasonics, Danbury, CT). The samples were then boiled for 10 min and 
spun for 20 s. The resulting supernatant was stored at -20°C until used. 
Polymerase Chain Reaction-Single Strand Conformation Poly-
morphism (PCR-SSCP) Analysis Exons S-8 of the p53 gene were 
amplified separately using upstream and downstream primers specific for 
each exon (Pierceall et al, 1991). Five microliters oftl1e lysates were used as 
templates in a 50-fLl solution containing 10 mM Tris-HCl (pH 8.3); 50 mM 
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Figure 1. Detection of p53 mutation by PCR-SSCP analysis in 
SCCs from PUV A-treated psoriasis patients. PCR-SSCP analysis of 
genonlic DNAs conesponding to exon 7 reveals aberrant bands (--+) in 
some tumors (Al, 14, 12, D2, K2, 13, and Hl), suggesting that these tumors 
may harbor mutations. In contrast, DNAs from human placenta (P) and 
tumors Dl, G1, and Kl do not show aberrant bands, wbich indicates that 
these samples may not have p5 3 mutations at ex on 7. 
KCI; 1.5 mM MgC12 ; 0.001% gelatin; 150 fLM each of dA TP, dGTP, dCTP, 
and dGTP; 2.5 fLCi of[a- 32P]dCTP; upstream and downstream primers (10 
fLM each) ; and 5 U AmpliTaq (PE Xpress, Foster City, CA). PCR was 
performed for two cycles at 94°C (1 min), 65°C (2 min), and n oc (2.5 
min); five cycles at 94°C (1 nun), 60°C (2 min), and 72°C (2.5 min); 30 
cycles at 94°C (1 min), ssoc (2 min) , and noc (2 .5 min); and finally one 
step at 72°C for 1 5 min. SSCP analysis was performed using a mutation 
detection enhancement ultra-high-reso lution gel (AT Biochem, Malvern, 
PA). In tlus analysis, 3 fLl of the PCR product was mixed with 7 fLl of 
sequencing stop solution, heated to 94°C for 5 min, quick-cooled on ice, 
and loaded onto a 0.25 X mutation detection enhancement gel. The gel was 
then run at 6 W for 14-1 8 h. Extreme precaution was taken to prevent 
contamination of PCR reactions, including the use of blank PCR controls 
without DNA templates and inclusion of human placental DNA in every 
PCR reaction. PCR-SSCP analysis was performed twice for each sample. 
Nucleotide Sequencing Wild-type and slufted (mutant) bands were cut 
out of the dried SSCP gels, and the DNA was eluted by incubating at 80°C 
for 30 min in 200 fLl of Tris-ethylenediamine tetraacetic acid. The eluted 
DNA was then reamplified by PCR, subcloned into pCR II vectors, and 
transformed according to tl1e manufacturer's instructions in tl1e TA clotling 
kit (Invitrogen Corporation, San Diego, CA) . Five to eight colonies from 
each sample were sequenced bidirectionally using M13(rev) and M13(-40) 
primers with Sequenase version 2.0 (USB, Cleveland, OH). In some cases, 
genomic DNA from SSCP-positive tumors was amplified by PCR and 
sequenced to confirm the mutation. In addition, to rule out PCR-generated 
mutations, we analyzed human placental DNA simultaneously in every 
PCR and sequencing reaction. 
RESULTS 
SCCs From PUVA-Treated Patients Display p53 Mutation 
by PCR-SSCP Analysis A total of 17 SCCs from 11 PUVA-
treated psoriasis patients were analyzed for p53 mutations by 
PCR-SSCP analysis in exons 5-8. About 90% of all mutations 
reported in all cancers occur between exons 5 and 8 of the p5 3 gene 
(Greenblatt eta/, 1994). Eleven of 17 (65%) SCCs examined had an 
altered SSCP pattern: 8 of 17 ( 4 7%) exllibi ted mutations in exon 7, 
and 4 of 17 (23.5%) had mutations in exon 8. ln addition, 1 tumor 
had a mutation in exon 5 and another tumor had one in exon 6 
(data not shown). T he representative SSCP profi.le of exon 7 shown 
in Fig 1 reveals both wild-type and shifted bands in 7 tumors but 
only wild-type bands, identical to those present in human placental 
DNA, in 3 other tumors. T he greater intensity of wild-type bands 
relative to mutant bands could reflect the possibility that only one 
p53 allele is mutated and the other is wild- type, that contan1inating 
normal cells are present in tumor tissues, or both. Similarly, in 
another SSCP gel, only 1 of 7 SCCs revealed aberrant bands at 
exon 7 (data not shown). In addition, 3 tumors had mutations in 
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more than one exon. For example, tumor I3 had mutations in exons 
5 and 7, tumorAl in exons 6 and 7, and tumor D2 in exons 7 and 
8 (data not shown). Because PCR-SSCP was performed for each 
exon separately, it was impossible to determine w hether multiple 
mutations in different exons occurred in the same p53 allele or in 
different alleles. Nonetheless, a second PCR-SSCP analysis of all17 
sees reveal ed that although the band intensities varied slightly, the 
band pattern for each exon was identical to that found in the first 
PCR-SSCP analysis. 
SCCs From PUV A-Treated Psoriasis Patients Contain Both 
PUV A-Type and UV-Type Mutations Aberrantly shifted and 
wild-type bands from dried SSCP gels were cut out, reconstituted, 
reamplified, and sequenced to identify the nature of the p53 
mutation. By this analysis, we detected a total of 24 missense 
mutations and 1 deletion in 11 of 17 SCCs (Table 1). Interestingly, 
tumor J2 had a 90-bp deletion (codons 269 to 299) in exon 8. 
Analogous to mutant bands, apparently normal-looking SSCP 
bands from several SCCs and human placental DNA were also 
subcloned and sequenced. In all cases, however, only the wild-type 
sequences were detected. More important, repeat analysis of 
genomic DNA from several tumors using PCR followed by 
subcloning and sequencing revealed p53 mutations that were 
identical to those found in the first analysis. Nonetheless, substitu-
tions at thymine bases (12 of 25; 48%) represented a significant 
portion of the p53 mutational spectra in PUVA-treated SCCs 
(Table 1). Of the 12 mutations, 8 were T~C transitions, 3 were 
T~A transversions, and 1 was a T~G transversion . 
In terms of sequence context for base substitutions at thymine, 
only one arose at 5 '-TpA, a known site of frequent PUV A-induced 
mutation (Sage et al, 1993; Yang at a/, 1994) . Two base su bstitu-
tions occurred at 5'-TpT sequences , whereas 9 of 12 (80%) 
occurred at 5' -TpG sites (Table 1). T he representative nucleotide 
sequence data shown in Fig 2 reveal that two tumors, D2 and A1, 
contained base substitutions at thymine in exon 7 at 5' -TpG and 
5' -TpA sites, respectively. Several mutations (8 of25; 32%) had the 
Table I. Types of p53 Mutations Detected in SCCs from 
PUV A-Treated Patients 
Surrounding 
Base Sequence Amino Acid 
Tun1or Ex on Codon Change (5'~3')" Change 
T3 5 135 G~T TTTGCC Cys~Phe 
5 139 T~A CT:.u:;,GG Lys~stop 
5 168 G~T TG:;ffiCT His~Tyr 
Gl 7 227 c~T GCTI:;,TG Ser~ Phe 
Hl 7 240 T~G AGTTCC Ser~Arg 
7 242 T~c CC1:G_CA Cys~Arg 
14 7 233 T~c AG:.u:;,GA His~Arg 
7 242 T~c CC1:G_CA Cys~A.rg 
K2 7 242 T~C CC.!G.CA Cys~Arg 
D2 7 242 T~c cc:.u:;,cA Cys~A.rg 
7 246 G~T CA:;ffiAC Met~ lie 
13 7 235 T-->C GT.!G.TA Asn~Asp 
Al 7 236 T~A ACTACA Tyr~Asn 
7 238 T~c TG:!:QTA Cys~Arg 
Kl 7 258 T~A TC:J::!:CC Glu~Val 
02 8 289 c~T AATCTC Leu~Phc 
8 293-294 cc~TT CTCCCC Glu~Lys 
8 294 - 295 cc~TT AGg;;TC Pro~Phc 
Cl 8 278 c~T TCTI:;,CT Pro~ Ser 
Jl 8 275 T~c TT.!G.TG Cys~Aia 
8 276 G~c TG:;ffiCC Ala~Pro 
8 289 c~T AATCTC Leu~Phe 
8 293-294 cc~TT C'l'CCCC Glu~Lys 
8 294-295 cc~TT AGCCTC Pro~Phe 
]2 8 269-299 Deletion 
11 The sequence is shown 5'~3' in the strand (transcribed or non transcribed) that has 
the thymine or the dipyrimidine bases. Mutated bases are shown in bold. S'TpG, 
S'TpA, S'TpT, and dipyrirnidinc seq uences are underlined. 
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Figure 2. Presence of missense mutations in p53 exon 7 in two 
SCCs . Nucleotide sequencing of PCR products from DNA isolated from 
dried SSCP ge ls corresponding to normal bands from human placental DNA 
(A,C) and aberrant bands from two tumor DNAs (B,D) reveals wild-type 
sequences in human placental DNA and mutant sequences in tumor DNAs. 
(B) tumorAl contains a T~A transversion in codon 236 at a 5'-TpA site, 
which resu lts in substitution of a tyrosine codon (TAC) by a codon fo r 
asparagine (AAC). (D) tumor D2 conta ins a T~C transition in codon 242 
at a 5 '-TpG site, which resu lts in substitution of a cys teine codon (TGC) by 
a codon for arginine (CGC ). The 5'~3' sequence is read from bottom to 
top. Wild-type and corresponding mutated bases arc shown (*) . 
UV signature (C~T or CC~TT transition) at dipyrimidine sites, 
primarily iJJ exon 8 (Table 1). Multiple mutations were found in 8 
of 12 tumors, some of which had base substitutions at thymine as 
well as C~T or CC~TT transitions. In addition, we detected a 
few silent mutations. For example, tumor A1 had an altered SSCP 
band in exon 6 that subsequent sequence analysis revealed to be a 
silent mutation (data not shown). Not all p53 mutations present in 
tumors contribute to tumor development, as some missense as well 
as silent mutations may arise after initiation because the population 
of cells is repeatedly exposed to PUV A or UVB, or both , during 
tumor progression. 
SCCs From PUV A-Treated Psoriasis Patients Exhibit Hot-
spots for p53 Mutation Analogous to p53 mutation hotspots in 
PUV A-induced murine skin cancers (Nata raj et a/, 1996), four 
human SCCs from PUV A-treated psoriasis patients contained 
identical T~ C transitions (predicting a Cys~ Arg substitution) at 
codon 242 (Table I; Fig 3). Interestingly, codon 242 is not 
frequently mutated in other types of hum au cancer, including skin 
cancer (Ziegler et al, 1993; Greenblatt et a/, 1994). In addition, two 
tumors had identical CC~TT transitions at codons 293-294 and 
294-295 and a C~T transition at codon 289 (Table 1). 
DISCUSSION 
Psoriasis patients as a group do not deviate from the general 
population with regard to the prevalence of internal malignancies 
(Lindelof et al, 1990), and p53 mutations have not been detected in 
psoriatic lesions (Moles eta/, 1993b) . One study reported that 46% 
of non-melanoma skin cancers from PUV A-treated psoriasis pa-
tients were immunopositive for p53 protein expression (Proby et a/, 
1993). Because p53 inmlUnostaining is not a good indicator of the 
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Figure 3. SCCs arising in PUV A-treated patients display hotspots 
for p53 mutation. The numbers of p53 mutations at various codons 
detected in SCCs were obtained from Table I and plotted on a g raph . 
Codon 242 is a hotspot for p53 mutation , followed by codons 289, 293-294, 
and 294 - 295. 
presence or absence of p53 gene mutations (Kubo et nl, 1994), 
however, it provides no information about the etiology of these 
cancers, as genetic analysis nught. Ln the current study, we analyzed 
skin cancers arisi11g in PUV A- treated psoriasis patients from Austria 
for p53 mutation to determine whether these skin cancers have a 
PUV A etiology or a UV etiology. Our p53 mutation analysis 
revealed a total of 24 missense mutations and 1 deletion in 11 of 17 
SCCs fi.·om psoriasis patients who had undergone PUV A therapy. 
Interestingly, 16 of 25 p53 mutations occurr~d in conserved 
domains II (amino acids 117-142), TV (amino acids 234 -258) , and 
V (amino acids 270-286). Almost all of the PUVA-type mutations 
(at 5'-TpG, 5'-TpT, and 5'-TpA sites) were in these conserved 
domains. It is noteworthy that both codon 242 (a hotspot for p53 
mutation in SCCs fro m PUV A-treated psoriasis patients) and codon 
238 code for cysteine, wluch represent two of the four binding sites 
fo r the tetrahedrally bound Zn2 + atom essential for the core 
structure. Mutations at these sites and in other conserved domains 
are predicted to destabilize the p53 protein (Cho et a/, 1994). Based 
on the crystal structure of the p53 core domain, it appears that the 
majority of the PUV A-type mutations affect the p53 structure more 
than the UV-type mutations (C~T and CC~TT) at codons 289, 
293-294, and 294-295, which are o utside these domains. 
Thirteen of25 mutations (52%) occurred at 5' -TpG sites, 2 of25 
at 5 '-TpT sites, and only l at a 5 'TpA site. Contrat-y to this finding, 
other studies have shown that 5 '-TpA sites are the primary targets 
for PUVA-induced mutagenesis (Sage et nl, 1993; Yang e/ a/, 1994; 
Chiou and Yang, 1995; Nataraj et al, 1996) and photoadduct 
formation (Boyer eta/, 1987; Sage and Moustacch.i, 1987; Sage and 
Bredberg, 1991), although base substitutions and mutations also 
occur at 5' -TpG and 5'-TpT sites (Miolo et nl, 1989; Sage, 1993; 
Yang et al, 1994; Chiou and Yang, 1995). It is not clear why 
5 ' -TpG and not 5 '-TpA sequences are the preferred targets for 
mutations in this population of tumors. It is possible that processing 
of psoralen adducts iu 11i11o in human s might be different and 
produce different p53 mutational spectra than in rodents or cells in 
culture. In addition, differences in site specificity between in 11itro 
and in viJJo studies could reflect the fact that very !ugh doses of 
PUV A, which do not mimic conditions in the clinic, were used in 
most in 11itro mutagenesis studies. This notion is supported by the 
finding that when murine fibroblasts containing supF DNA were 
treated with low, clinically relevant doses ofPUV A (5 J.LM 8-MOP 
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+ 0.1j/cm2 UVA), on ly 19°ft, ofthe mutations occurred at 5' -TpA 
sites after PUV A treatment (Gunther eta/, 1995). More important, 
a greater number (12 of 42; 29%) of mutations occurred at 5' -TpG 
sites . 
It is noteworthy that 32% of the p53 mutations we detected in 
SCCs from Austrian PUVA-treatcd patients were UV-signature 
mutations (C~T or CC~TT transitions) at dipyrimidine sites . 
T here could be several explan ations why UV-signature mutations 
were present in SCCs fi-om some PUV A- treated psoriasis patients . 
First, most psoriasis patients in Austria receive UVB therapy before 
PUVA therapy. In fact , in our cohort, 9 of 11 patients had prior 
treatment with UVB. Strikingly, a11 4 tumors harboring UV-
signature mutations (Cl, D2, Gl, and J1) arose in patients w ho 
were treated previously w ith UVB radiation . Second, because 
exposure to sunlight was thought to be beneficial for psoriasis, the 
patients were encouraged to get ample exposure to sunlight. Third, 
the PUV A lamps used in psoriasis therapy in Austria emit about 
0.5% of the total energy in the UVB region (below 320 nm). 
Fourth, because PUV A exposure also generates reactive O}..rygen 
species (Carraro and Pathak, 1991; Potapenko, 1991), wluch are 
known to induce CC~TT transitions (Reid and Loeb, 1993), it is 
possible that the CC~TT mutations found in som e SCCs from 
PUV A-treated patients were induced by reactive oxygen intenne-
diates. 
Nonetheless, our results indicate that the p53 mutation spectra 
seen in SCCs from Austrian PUVA-treated psoriasis patients are 
intrinsically different from those seen in sees from the general 
(nonpsoriatic) population (Fig 4). For instance, 16 of25 (64%) p53 
mutations detected in SCCs from PUV A-treated patients were 
located at putative sites of psoralen photoaddition (5 ' -TpA, 5 '-
TpG, or 5 '-TpT) IJCJ"SIIS only 22% at the same regions in sees from 
the general population (chi-square test for PUVA subgroup; p = 
0.0017). Interestingly, about 32% of p53 mutations in SCCs from 
PUVA-treated patients had the UV-signature (C~T and 
CC~TT), which is comparable to th e 43% frequency in SCCs 
arising in the general population (chi-square test for UV subgroup; 
p = 0.416). In addition to these differences, SCCs from PUVA-
treated psoriasis patients exhibited hotspots for p5 3 mutations at 
codon 242 and, to a lesser extent, at codons 289, 293- 294, and 
294 - 295 (Fig 3). This could be attributed to the inefficient repair of 
PUV A- and/ or UV -induced photoproducts at these sites . In sup-
port of this notion , Tornaletti and Pfeiffer (1994) demonstrated that 
highly mutated sites in p5 3 are regions of slow DNA repair of UV 
lesions. 
T he p5 3 mutations detected in SCCs from PUV A-treated psori-
asis patients cannot be attributed to the persistence of DNA damage 
A 8 
4% 
32% 
•PUVA-type mutations (at 5'-TpG, 5'-TpA or 5'-TpT sites) 
0 UV-type mutations (C - Tor CC - TT transition at dlpyrlmldlne sites) 
IS:lOthers 
Figure 4. The p53 mutation spectra of hmnan SCCs from PUV A-
treated psoriasis patients differ from those reported in sees front 
the general population. (A) p53 mutation data for SCCs from PUVA-
treatcd patients wq.e obtained fi·om Table I (n = 25). (B) p53 mutation data 
for human sees limn the general population were pooled from four srudies 
(Brash el nl, "1991; Pierceall et a/, 1991 ; Moles ct. nl , 1993a; Nelson et a{·, 
1994). A tota.l of 28 mutations were included in thi s analysis. 
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in skin tumors that gave rise to mutations during PCR because most 
sees that had mutations arose in patients 3 mo to 11 y after the last 
PUVA treatment, and it is unlikely that the DNA damage persists 
for such a long time . Several studies have shown that a majority of 
PUV A- and UVB-induced DNA lesions in eukaryotic cells are 
repaired in 48-72 h (Vos and Hanawalt, 1987; Zarebska et a/, 
1987) . Moreover, our previous studies have shown that PUV A-
exposed mouse skin adjacent to the tumor did not have p53 
mutations (Nataraj et a/, 1996) . In addition, we can rule out the 
possibility that the mutations found in SCCs were due to PCR 
artifacts because we detected identical mutations by two separate 
PCR and sequencing analyses of genomic DNA from some tumors, 
and PCR-SSCP and nucleotide sequencing of human placental 
DNA did not reveal p53 mutations in exons 5-8. 
Finally, the identification of carcinogens responsible for the 
induction of human cancers, based on the mutational fingerprint, is 
quite complex. Some patients in tlus study also had prior treatment 
with arsenic and methotrexate, although there are no conclusive 
data linking these compounds with p53 mutations. Complicating 
factors notwithstanding, our study shows that both PUV A and UV 
may be responsible for the induction of skin cancer in PUV A-
trea ted p soriasis patients in Austria. Because the PUVA therapy 
regimen used in treating psoriasis patients in the United States is 
different from that used in Austria, it remains to be determined 
whether SCCs from PUVA-treated patients in the United States 
contain the PUVA or UV type of p53 mutation, or both. Such 
studies are currently under way. 
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